KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesDividends payablesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Accumulated Expenses (2016 - 2025)

Abbott Laboratories' Accumulated Expenses history spans 17 years, with the latest figure at $1.7 billion for Q4 2025.

  • For Q4 2025, Accumulated Expenses rose 2.59% year-over-year to $1.7 billion; the TTM value through Dec 2025 reached $1.7 billion, up 2.59%, while the annual FY2025 figure was $1.7 billion, 2.59% up from the prior year.
  • Accumulated Expenses for Q4 2025 was $1.7 billion at Abbott Laboratories, up from $1.7 billion in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $1.7 billion in Q4 2025 and bottomed at $1.1 billion in Q1 2024.
  • The 5-year median for Accumulated Expenses is $1.4 billion (2021), against an average of $1.4 billion.
  • The largest annual shift saw Accumulated Expenses grew 17.7% in 2021 before it decreased 4.27% in 2023.
  • A 5-year view of Accumulated Expenses shows it stood at $1.6 billion in 2021, then decreased by 4.25% to $1.6 billion in 2022, then rose by 2.63% to $1.6 billion in 2023, then rose by 6.51% to $1.7 billion in 2024, then rose by 2.59% to $1.7 billion in 2025.
  • Per Business Quant, the three most recent readings for ABT's Accumulated Expenses are $1.7 billion (Q4 2025), $1.7 billion (Q3 2025), and $1.6 billion (Q2 2025).